The combination of a custom mRNA vaccine with standard treatment showed encouraging results against solid tumours in the latest clinical data.
Tag: Intismeran
Personalized Cancer Vaccine Intismeran Autogene Shows Promising Phase 2 Results at ASCO 2026
Phase 2 trial presented at ASCO annual conference shows that the personalized mRNA cancer vaccine intismeran autogene improves outcomes in solid tumors